Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd. ("Shangyao Zhongxi"), recently received the "Drug Registration Certificate" (Certificate No.: 2025S03175) from the National Medical Products Administration (NMPA) for Pyridostigmine Bromide Sustained-Release Tablets, approving its production.

Pyridostigmine Bromide Sustained-Release Tablets are used to treat myasthenia gravis and were originally developed by BAUSCH, first approved in the U.S. in 1959. In March 2024, Shangyao Zhongxi submitted a registration application for the drug to the NMPA, which was subsequently accepted.

As of the announcement date, the company has invested approximately RMB 16.009 million in R&D for this drug. Currently, no other domestic manufacturers have launched Pyridostigmine Bromide Sustained-Release Tablets in China.